Can Biologic DMARDs Protect Against Sepsis?

By

Biologic DMARDs (bDMARDs) confer a protective effect in patients with rheumatoid arthritis, lowering risk of developing sepsis as well as reducing mortality after serious infection and sepsis, according to results from a German registry presented at the 2015 ACR/ARHP Annual Meeting.

Methotrexate May Boost Golimumab in Psoriatic Arthritis

By

Adding methotrexate (MTX) to golimumab (GLM) therapy might significantly improve some symptoms among patients diagnosed with psoriatic arthritis (PsA), suggests a study reported at the 2015 ACR/ARHP Annual Meeting.

Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Flares?

By

Dietary omega-3 fatty acid-rich fish consumption, but not omega-3 supplements alone, confer a protective effect against recurrent gout attacks, reported MaryAnn Zhang, MD, from the Boston University School of Medicine, Boston, MA, at the 2015 ACR/ARHP Annual Meeting.

Is Non-TNF Targeted Tx Better Than a Second Anti-TNF Drug?

By

A non-TNF-targeted biologic showed better efficacy than a second anti-TNF agent for patients with rheumatoid arthritis and insufficient response to TNF-inhibitors, according to research presented at the 2015 ACR/ARHP Annual Meeting.

Mavrilimumab Effective Long-Term in RA Disease Activity

By

Long-term administration of mavrilimumab is safe and offers sustained clinical efficacy against moderate-to-severe rheumatoid arthritis (RA), according to an open-label extension study reported at the 2015 ACR/ARHP Annual Meeting

Ustekinumab Beneficial in Patients With Psoriatic Arthritis with Spondylitis and Peripheral Joint Involvement

By

Ustekinumab (UST) benefits patients with psoriatic arthritis (PsA) with spondylitis and peripheral joint involvement, according to an post-hoc analysis of results from the PSUMMIT 1 & 2 phase 3 double-blind, placebo-controlled clinical trials, reported at the 2015 ACR/ARHP Annual Meeting.

Apremilast Safe, Effective at 3 Years in Psoriatic Arthritis

By

Longer-term efficacy and safety data from the Phase 3 PALACE 1 study have confirmed that apremilast continues to demonstrate sustained and clinically meaningful improvements in psoriatic arthritis signs and symptoms at 3 years in patients who remained on the treatment, investigators concluded at the 2015 ACR/ARHP Annual Meeting.

Pregabalin Safe in Fibromyalgia Whether Baseline Pain Moderate or Severe

By

The safety and tolerability of pregabalin for the treatment of fibromyalgia-associated pain does not differ by baseline pain severity, a pooled analysis of five phase 3 clinical trials presented at the 2015 ACR/ARHP Annual Meeting has shown.

PDE5 Inhibitors Beneficial in Raynaud's Phenomenon

By

Phosphodiesterase 5 (PDE5) inhibitors appear to be effective in treating Raynaud's phenomenon secondary to scleroderma, investigators concluded at the 2015 ACR/ARHP Annual Meeting.

Golimumab Reduces Symptom Severity in Ankylosing Spondylitis

By

Golimumab was well tolerated and effective in reducing symptom severity and improving disease outcomes in patients with ankylosing spondylitis over 12 months, a Canadian longitudinal study reported at the 2015 ACR/ARHP Annual Meeting.

No 'Significant Renal Safety Signals' With Tabalumab in SLE

By

Treatment with tabalumab did not significantly affect serum creatinine, glomerular filtration rate, or urine protein/creatinine ratio over 52 weeks vs. placebo, investigators reported at the 2015 ACR/ARHP Annual Meeting.

Golimumab Improves QoL, Work Productivity in Axial Spondyloarthritis

By

Data presented at the 2015 ACR/ARHP Annual Meeting showed that patients with active nonradiographic axial spondyloarthritis who received golimumab showed greater improvement in quality of life and work productivity outcomes than placebo.

Skin Tests Predict Anti-TNF Hypersensitivity Reactions in RA, AS Patients

By

Patients with rheumatoid arthritis (RA) and ankylosing spondylitis (AS) who develop hypersensitivity reactions to infliximab, etanercept and adalimumab are more likely to have positive skin tests despite the absence of an overall relationship with antidrug antibody (ADA) levels, according to a study reported at the 2015 ACR/ARHP Annual Meeting.

IV to SC Abatacept Switch Might Diminish Efficacy for Some RA Patients

By

Transitions from intravenous to subcutaneous administration of abatacept may be associated with diminished disease control in some patients with rheumatoid arthritis (RA), according to a study reported at the 2015 ACR/ARHP Annual Meeting.

Analysis: No Cardiovascular Benefits for Xanthine Oxidase Inhibitors

By

Xanthine oxidase inhibitors (XOIs) do not improve uric acid-associated risks for cardiovascular events or deaths among adults, according to a meta-analysis of data pooled from 61 randomized controlled clinical studies, which was reported at the 2015 ACR/ARHP Annual Meeting.

Do Pre-Pregnancy Biologic DMARDs Increase the Risk of Birth Defects?

By

In women with long-standing rheumatic disease there was "no significantly increased risk of malformations or other harmful consequences" in those "exposed to biologic disease-modifying antirheumatic drugs (bDMARDs) before or at conception," results of a study reported at the 2015 ACR/ARHP Annual Meeting have found.

Canakinumab Effective for Long-term Management of Acute Gouty Arthritis Flares

By

The selective human anti-interleukin-1β antibody canakinumab demonstrates long-term safety and efficacy for patients with acute gouty arthritis flares, according to a follow-up study reported at the 2015 ACR/ARHP Annual Meeting.

Colchicine May Prevent Acute Cardiovascular Events in Gout Patients

By

In patients with gout, chronic colchicine use has no effect on the rate of incident coronary artery disease (CAD), a study presented at the 2015 ACR/ARHP Annual Meeting concluded.

Among All Chronic Arthritides, Golimumab Drug Survival High at 2 Years

By

Golimumab appears to have similar drug survival at two years in different chronic arthritides regardless of prior biological disease modifying drug (bDMARD) treatment, results of a multicenter prospective observational study reported at the 2015 ACR/ARHP Annual Meeting.

Golimumab Reduces Burden of Illness in Psoriatic Arthritis

By

Golimumab ameliorated the significant burden of illness observed in psoriatic arthritis at treatment initiation, reducing symptom severity and improving disease outcomes over 12 months, a study of patients in routine clinical practice in Canada presented at the 2015 ACR/ARHP Annual Meeting has found.